Rituximab Combined With Chidamide and Lenalidomide for r/r AITL

Summary

This study is designed to explore the effeicency and toxicities of rituximab combined with chidamide and lenalidomide in patients with relapsed or refractory AITL.

Timeline

Start

2020-03-13

Primary completion

2022-03-31

Completion

2022-12-31

Publications

• Li C, Lei T, Xu X, Lu J, Zhu X, Chen Z, Weng X, Yu H, Chen X, Peng S, Han S, Yang H. RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma. Am J Hematol. 2026 May 12. doi: 10.1002/ajh.70366. Online ahead of print.

Drugs

Indications